Published in:
01-12-2020 | Esophagus Resection | Correction
Correction to: Thoracic Duct Resection During Esophagectomy Does Not Contribute to Improved Prognosis in Esophageal Squamous Cell Carcinoma: A Propensity Score Matched-Cohort Study
Authors:
Taro Oshikiri, MD, Gosuke Takiguchi, MD, Susumu Miura, MD, Hironobu Goto, MD, Dai Otsubo, MD, Hiroshi Hasegawa, MD, Masashi Yamamoto, MD, Shingo Kanaji, MD, Kimihiro Yamashita, MD, Takeru Matsuda, MD, Yasuhiro Fujino, MD, Masahiro Tominaga, MD, Tetsu Nakamura, MD, Satoshi Suzuki, MD, Yoshihiro Kakeji, MD
Published in:
Annals of Surgical Oncology
|
Special Issue 3/2020
Login to get access
Excerpt In the original article, there are errors in Fig. 1. Following is the corrected figure (Fig.
1 ).
Fig. 1
a The 5-year OS rate for patients of all stages was 60% among the 122 TD-preserved patients versus 49% among the 122 TD-resected patients (P = 0.08). b The 5-year DFS rate for patients of all stages was 57% among the 122 TD-preserved patients versus 53% among the 122 TD-resected patients (P = 0.35). c The 5-year CSS rate for patients of all stages was 70% among the 122 TD-preserved patients versus 58% among the 122 TD-resected patients (P = 0.08). d The 5-year OS rate for c-stage IA patients was 81% among the 25 TD-preserved patients versus 83% among the 25 TD-resected patients (P = 0.76). e The 5-year DFS rate for c-stage IA patients was 91% among the 25 TD-preserved patients versus 92% among the 25 TD-resected patients (P = 0.95). f The 5-year CSS rate for c-stage IA patients was 96% among the 25 TD-preserved patients versus 92% among the 25 TD-resected patients (P = 0.64). g The 5-year OS rate for c-stage IB–IV patients was 51% among the 96 TD-preserved patients versus 44% among the 96 TD-resected patients (P = 0.21). h The 5-year DFS rate for c-stage IB–IV patients was 50% among the 96 TD-preserved patients versus 46% among the 96 TD-resected patients (P = 0.54). i The 5-year CSS rate for c-stage IB–IV patients was 58% among the 96 TD-preserved patients versus 51% among the 96 TD-resected patients (P = 0.30). c-stage clinical stage, OS overall survival, DFS disease-free survival, CSS cancer-specific survival, TD thoracic duct
×
…